Literature DB >> 6609822

Mechanism of T lymphocyte activation by OKT3 antibodies. A general model for T cell induction.

U Landegren, J Andersson, H Wigzell.   

Abstract

The OKT3 monoclonal antibody has unique reactivity for human T cells and induces a mitogenic response equal to that of concanavalin A (Con A). However, significant differences were found in activation requirements for the two T cell mitogens. Although both OKT3 and Con A required living accessory cells for stimulation of T cells, the OKT3 antibody was optimally mitogenic at a molar concentration 10(3) times less than Con A. Under such conditions, the two mitogens showed similar kinetics as well as magnitude or responses. Furthermore normal IgG blocked the OKT3-induced proliferation selectively. The inhibition is most likely caused by the Fc portion of IgG competing for Fc receptors on accessory cells. The different requirements for activation are discussed in relation to the T cell receptor and its role in T cell activation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609822     DOI: 10.1002/eji.1830140409

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

Review 1.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

2.  T-cell activation by anti-idiotypic antibody: evidence for the internal image.

Authors:  A D Rees; K Praputpittaya; A Scoging; N Dobson; J Ivanyi; D Young; J R Lamb
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

3.  Respective contribution of intracellular calcium release and extracellular calcium influx for interleukin-2 synthesis in activated T-cell hybrids.

Authors:  D B Williams; M A Perera; K J Dorrington; M H Klein
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

4.  An engineered ultra-high affinity Fab-Protein G pair enables a modular antibody platform with multifunctional capability.

Authors:  Tomasz Slezak; Lucas J Bailey; Mateusz Jaskolowski; Dominik A Nahotko; Ekaterina V Filippova; Elena K Davydova; Anthony A Kossiakoff
Journal:  Protein Sci       Date:  2019-11-01       Impact factor: 6.725

5.  Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates.

Authors:  G Jung; J A Ledbetter; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

6.  Role in T-cell activation for HLA class I molecules from accessory cells: further distinction between activation signals delivered to T cells via CD2 and CD3 molecules.

Authors:  S Huet; L Boumsell; B Raynal; L Degos; J Dausset; A Bernard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

7.  Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.

Authors:  Tanaya Vaidya; Robert M Straubinger; Sihem Ait-Oudhia
Journal:  Pharm Res       Date:  2018-03-13       Impact factor: 4.200

8.  Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.

Authors:  P M Anderson; F H Bach; A C Ochoa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  Functional characterization of an antigen involved in an early step of T-cell activation.

Authors:  M E Cosulich; A Rubartelli; A Risso; F Cozzolino; A Bargellesi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

10.  Implications for the role of cognate interactions in in vitro human B cell activation by Staphylococcus aureus Cowan I and pokeweed mitogen.

Authors:  N Suzuki; T Sakane; Y Ueda; Y Murakawa; T Tsunematsu
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.